MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
MADRIGAL PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$447.09−2.65 (-0.59%)
Close on Oct 19, 2026
- Market cap
- $13.03B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
-31.3%
Net margin
-30.1%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +432.1% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 422.1% | -61.6% | -42.5% | |
| Return on assets | -126.9% | -55.5% | -25.0% | |
| Current ratio | 8.58 | 6.13 | 4.01 | |
| Debt to equity | – | – | 0.56 | |
| Net debt to EBITDA | – | – | -0.47× | |
| Interest coverage | -20.8× | – | -13.5× | |
| Capex to revenue | – | – | 0.0% | |
| Diluted shares | 5M | 15M | 28M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Madrigal Pharmaceuticals generated $1.38B from operations and spent $3.83M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.38B
Used
$3.83M
Capital expenditure$3.83M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-30.1%
×Asset turnover0.83×
×Equity multiplier1.70×
=Return on equity, FY2025-42.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -30.1% | 0.83× | 1.70× | -42.5% |
| FY2024 | -258.6% | 0.21× | 1.45× | -80.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$288.28M
- Cash generatingOperating cash flow above zero-$189.55M
- Return on assets improvedROA up on the prior year-72.7% → -27.7%
- Earnings backed by cashOperating cash flow above net income-$189.55M vs -$288.28M
- Less leverageLong-term debt to assets fell11.3% → 27.0%
- Better liquidityCurrent ratio rose6.10 → 4.01
- No dilutionShare count did not rise27M → 28M
- Gross margin improvedGross margin up on the prior year96.54% → –
- More efficientAsset turnover rose0.28 → 0.92